TWI656131B - Use of nrf-1 protein in the manufacture of a medicament for treatment of bladder cancer - Google Patents

Abstract

A use of NRF-1 protein is to prepare a medicine for treating bladder cancer, wherein the NRF-1 protein has an amino acid sequence as shown in SEQ ID NO: 1 and is administered to a desired individual in order to Treatment of bladder cancer.

Description

Use of NRF-1 protein for preparing medicine for treating bladder cancer

The invention relates to the use of an NRF-1 protein, in particular to the use of an NRF-1 protein to prepare a medicament for treating bladder cancer.

Bladder cancer is one of the common tumors in the urology department. It refers to a variety of cancers that occur in the bladder, and the most common is transitional cell carcinoma (TCC). Generally speaking, the treatment methods of bladder cancer include surgery, immunotherapy, chemotherapy and radiation treatment, but there are no effective drugs for the treatment of bladder cancer. Therefore, there is still a need to provide a use of NRF-1 protein to improve the aforementioned problems. .

In order to solve the above problems, the present invention provides the use of an NRF-1 protein, and the NRF-1 protein is used to prepare a drug for treating bladder cancer.

The use of the NRF-1 protein according to the present invention is to prepare a drug for treating bladder cancer, wherein the NRF-1 protein has an amino acid sequence as shown in SEQ ID NO: 1 and is administered to a Individuals are required to treat bladder cancer; for example, the required individual is administered at a dose of 50 to 100 micrograms per kilogram of body weight per day, once a day for 7 consecutive days; preferably, 70 is administered per kilogram of body weight per day A microgram dose is administered to the desired individual; thus using NRF-1 protein as an active ingredient, it can effectively cause cytotoxicity to bladder cancer cells, and inhibit the proliferation and survival of bladder cancer cells, so it can be applied to the preparation of drugs for treating bladder cancer It is the effect of the present invention.

The use of the NRF-1 protein according to the present invention, wherein the NRF-1 protein It is administered to the desired individual parenterally or parenterally; in this way, the NRF-1 protein can be prevented from losing its activity by the action of the digestive tract.

Figure 1a: Short-term transfection of the NRF-1 protein of the present invention can reduce the cell proliferation rate of human bladder cancer cell lines.

Figure 1b: Short-term transfection of the NRF-1 protein of the present invention can reduce the cell survival rate of human bladder cancer cell lines.

Figure 1c: Short-term transfection of the NRF-1 protein of the present invention can cause cytotoxicity to human bladder cancer cell lines.

In order to make the above and other objects, features, and advantages of the present invention more comprehensible, the following describes the preferred embodiments of the present invention and the accompanying drawings in detail, as follows:

The "NRF-1 (nuclear respiratory factor 1) protein" according to the present invention has an amino acid sequence as shown in SEQ ID NO: 1, for example, it may be a sequence comprising a nucleotide as shown in SEQ ID NO: 2 The expression of the vector of the sequence is continuously obtained by protein purification, and the selection of the vector, the construction of the vector that can express the NRF-1 protein, the expression, and the protein purification are all required by those with ordinary knowledge in the technical field to which the present invention belongs. The ability to adjust itself is not limited here.

The NRF-1 protein of the present invention can be administered to a desired individual. For example, the NRF-1 protein can be purified and then administered to the desired individual at a dose of 50 to 100 micrograms per kilogram of body weight per day. For 7 consecutive days, it can be administered to the desired individual at a dose of 70 micrograms per kilogram of body weight per day, which further causes cytotoxicity to bladder cancer cells and inhibits the proliferation and survival of bladder cancer cells, so it can be applied to Preparation of medicine for treating bladder cancer.

The NRF-1 protein of the present invention may also be associated with at least one pharmaceutically acceptable The carriers together form a pharmaceutical composition, or other pharmaceutical active ingredients are additionally added to the pharmaceutical composition for co-administration to the desired individual. The carrier is an excipient or an additive, preferably it can be An appropriate dose is regularly administered to the desired individual parenterally or parenterally, for example, the desired individual can be administered by injection to prevent the NRF-1 protein from losing its activity due to the action of the digestive tract. .

In order to confirm that the NRF-1 protein of the present invention can indeed cause cytotoxicity to bladder cancer cells, and inhibit the proliferation and survival of bladder cancer cells, and then can be used to prepare drugs for treating bladder cancer, a test was performed with human bladder cancer cell line T24. Cells without short-term transfection were used as group A0, cells with short-term transfection control group (pcDNA-control) were used as group A1, and short-term transfection could express the plastids of the NRF-1 protein (pcDNA- NRF1) cells were used as group A2, as shown in Table 1.

First, the effect of short-term transplantation of NRF-1 protein on the cell proliferation rate of human bladder cancer cell lines was analyzed by MTT method. The cell proliferation rate of human bladder cancer cell line group A0 without short-term transplantation was taken as 100%. As a result, as shown in Fig. 1a, the cell proliferation rate of the human bladder cancer cell line A2 of the short-term transplantation of the NRF-1 protein significantly decreased, showing that the NRF-1 protein can reduce the cells of the human bladder cancer cell line. Proliferation rate.

Then trypane blue staining was used to analyze the effect of short-term transfection of NRF-1 protein on the cell survival rate of human bladder cancer cell lines. The cell survival rate is taken as 100%, and the result is as shown in Section 1b. As shown in the figure, the cell survival rate of the human bladder cancer cell line A2 of the short-term transgenic NRF-1 protein significantly decreased, showing that the NRF-1 protein can reduce the cell survival rate of the human bladder cancer cell line.

Finally, the LDH method was used to evaluate the cytotoxicity of the short-term transgenic NRF-1 protein on human bladder cancer cell lines, and the cell survival rate of the lysed human bladder cancer cell lines was taken as 100% (not shown). The results are as follows: As shown in Figure 1c, short-term transfection of the NRF-1 protein did cause cytotoxicity to human bladder cancer cells (Group A2).

In summary, the NRF-1 protein of the present invention causes cytotoxicity to bladder cancer cells, and inhibits the proliferation and survival of bladder cancer cells, so it can be applied to the preparation of drugs for treating bladder cancer, which is the efficacy of the present invention.

Although the present invention has been disclosed using the above-mentioned preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications to the above embodiments without departing from the spirit and scope of the present invention. The technical scope protected by the invention, so the scope of protection of the present invention shall be determined by the scope of the appended patent application.

<110> Yang Yilin

<120> Use of NRF-1 protein for preparing medicine for treating bladder cancer

<130> PK13987

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 503

<212> PRT

<213> Homo sapiens

<400> 1

<210> 2

<211> 1512

<212> DNA

<213> Homo sapiens

<400> 2

Claims (4)

A use of NRF-1 protein is to prepare a medicine for treating bladder cancer, wherein the NRF-1 protein has an amino acid sequence as shown in SEQ ID NO: 1 and is administered to a desired individual in order to Treatment of bladder cancer. The use of the NRF-1 protein as described in item 1 of the patent application scope, wherein the NRF-1 protein is administered to the desired individual parenterally or parenterally. According to the use of the NRF-1 protein described in item 1 of the scope of the patent application, wherein the NRF-1 protein is administered to the required individual at a dose of 50 to 100 micrograms per kilogram of body weight per day, once per day, 7 consecutive days. The use of the NRF-1 protein as described in item 3 of the patent application scope, wherein the NRF-1 protein is administered to the desired individual at a dose of 70 micrograms per kilogram of body weight per day.